Navigation Links
Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Date:9/23/2008

ch and Development for Arisyn. "The compounds have proven efficacy and safety in preclinical studies and have shown significant promise to progress to Phase 1 human clinical trials for the treatment of HIV and cancer."

The continued preclinical and clinical development of the compound portfolio will be performed by ImQuest BioSciences, a Contract Research Organization located in Frederick, MD specializing in the development of drugs for the treatment of infectious disease and cancer. ImQuest will perform necessary preclinical and clinical studies and manage the evaluation of Arisyn's compounds in human clinical trials, as well as assist Arisyn with the discovery of next generation inhibitors of the novel therapeutic targets.

Bo Statham, UTR Manager, said he is very pleased that this promising technology has been assigned to Arisyn, a company that will focus exclusively on the development of these drugs.

About UTR

UTR is a limited liability company that was established to benefit the University of Arizona in the development of patents and other technology and to license or otherwise transfer such intellectual property to third parties.

About Arisyn Therapeutics Inc.

Arisyn Therapeutics Inc. is a privately held biotechnology company focused on the clinical development of small molecule therapeutics for infectious diseases and cancer. Arisyn's strategy is to develop novel inhibitors with unique mechanisms of action for chronic diseases without effective therapeutic options such as HIV, hepatitis, and cancer. Arisyn Therapeutics Inc. is based in Frederick, Maryland and is on the web at http://www.Arisyn.com.

About ImQuest BioSciences, Inc.

ImQuest BioSciences, a privately held U.S. company located in Frederick, Maryland is a leading provider of anti-infective therapeutic and microbicide development and anti-cancer services to the biotechnology and pharmaceutical ind
'/>"/>

SOURCE Arisyn Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced today ... Officer, will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. ... the presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a ...
(Date:9/2/2014)... 2014 Culot brings life science ... management services  BioData, producer of Labguru, the ... announce the appointment of Louis Culot as ... VP Marketing and Business Development at BioDiscovery Inc., developer ... applications. Previously, Culot worked for 17 years ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
(Date:8/29/2014)... Aug. 29, 2014  Pfenex Inc. (NYSE MKT: ... development of high-value and difficult to manufacture proteins ... and reported financial results for the second quarter ... successful completion of our initial public offering, we ... biosimilar product candidates, derived from our proprietary protein ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Axial Biotech, Inc., a company,revolutionizing spine care ... technologies, announced today that it has met several,major ... genetic,prognostic test for Adolescent Idiopathic Scoliosis (AIS) and ... B financing. The Series B financing was,led by ...
... The rating,agency Moody,s has raised the rating ... "Outlook stable"., As a result, the Group,s ... are substantially enhanced. Moody,s justifies,this step by reference ... of successful acquisitions and in view of the ...
... Conference Call/Webcast to be Wednesday, March 19 at 10:00 ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) will host a ... and year ended December 31,2007 on Wednesday, March 19, ... the conference call can be accessed through the,company,s Web ...
Cached Biology Technology:Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2Moody's Raises Rating for Gerresheimer 2Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results 2
(Date:9/2/2014)... From AGU,s blogs: Earthquake rupture through a U.S. suburb ... University of California Davis in the hours and days ... helping scientists understand why the earthquake caused so much ... The Trembling Earth blog, hosted by the American Geophysical ... Future Mars Rovers: The Next Places to Direct Our ...
(Date:9/2/2014)... September 3, The Field Museum will present the prestigious ... of his commitment to biodiversity conservation awareness. The Parker/Gentry ... an outstanding individual, team or organization whose efforts have ... natural heritage and whose actions can serve as a ... of Mongabay.com, an environmental science and conservation news website ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... toward EAC standard by providing ... a single platform, DALLAS, Sept. 10 As ... globe, many seek a method,to deploy border security capabilities ... ENTU ) and 3M (NYSE: MMM ),announce ...
... ,Empowering People & Commerce, WALL, N.J., Sept. ... a leader in finger-based biometric,identification and wireless public ... 2008 Biometric Technology Expo, to be held in,conjunction ... 23 - 25 at the Tampa Convention Center ...
... been awarded $1 million from the US Department of ... conversion technologies. The grant is one of six awarded ... their advanced biofuels projects. In total, the DOE will ... for their research into how non-food feedstocks can be ...
Cached Biology News:Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 2Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 3Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 4BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 2BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 3Stevens awarded $1M for advanced biofuels research 2
biotin-4-fluorescein...
Human IL-17D Affinity Purified Polyclonal Ab...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: